What is the equity of BB Biotech this year?
BB Biotech has equity of 2.32 B CHF this year.
BB Biotech Equity 2024
BB Biotech Equity
2.32 B CHF
Ticker
BION.SW
ISIN
CH0038389992
WKN
A0NFN3
In 2024, BB Biotech's equity was 2.32 B CHF, a -13.51% increase from the 2.69 B CHF equity in the previous year.
BB Biotech Aktienanalyse
What does BB Biotech do?
BB Biotech AG is a Swiss investment company specializing in biotechnology and life sciences. The company was founded in 1993 and has been listed on the SIX Swiss Exchange since 1995. BB Biotech AG primarily invests in publicly traded companies in Europe and North America that are active in the biotechnology and healthcare industry. The business model of BB Biotech AG is based on a combination of active portfolio management and long-term investment strategy. The company invests in stocks of biotechnology and healthcare companies that typically do not yet generate profits but are developing promising products or technologies. BB Biotech AG focuses on high portfolio diversification to minimize risk. BB Biotech AG is divided into three business areas: biotechnology, pharmaceuticals, and medtech. The emphasis is on biotechnology, where the company invests in stocks of well-known biotech companies such as Celgene, Gilead Sciences, Regeneron, and Biogen. In the pharmaceutical sector, BB Biotech AG invests in large pharmaceutical companies like Roche, Novartis, or Pfizer. In the medtech sector, the company invests in companies specializing in the development of medical devices and instruments, such as Intuitive Surgical or Neurocrine Biosciences. BB Biotech AG provides added value to its investors through continuous monitoring of the companies in the portfolio and risk management. The company ensures that investors are always informed about the latest developments in the biotechnology and healthcare industry and regularly publishes reports about the portfolio. The portfolio of BB Biotech AG consists of over 30 different biotech, pharmaceutical, and medtech companies. The main holdings of BB Biotech AG are Celgene, Gilead Sciences, Biogen, Incyte, Vertex Pharmaceuticals, Regeneron, and Neurocrine Biosciences. Celgene is one of the world's leading biotech companies specializing in the development of drugs against cancer and other serious diseases. Gilead Sciences is a biotech company specializing in the research of new therapies for the treatment of infectious diseases such as HIV and hepatitis. Biogen is a biotech company specializing in the treatment of neurological disorders such as multiple sclerosis. Incyte is a biotech company specializing in the development of drugs against cancer and inflammatory diseases. Vertex Pharmaceuticals is a biotech company specializing in the treatment of cystic fibrosis. Regeneron is a biotech company specializing in the development of drugs against eye diseases such as macular degeneration and other serious diseases. Neurocrine Biosciences is a medtech company specializing in the development of drugs against sleep disorders and other neurological diseases. BB Biotech AG is an important player in the market for biotechnology and healthcare investments. Through smart selection of investment targets and systematic risk monitoring, the company has enabled investors to achieve high returns with comparatively low risk. Due to these factors, it is now one of the most important holdings in the biotechnology and healthcare sector. BB Biotech ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing BB Biotech's Equity
BB Biotech's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding BB Biotech's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating BB Biotech's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
BB Biotech's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in BB Biotech’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about BB Biotech Stock
What was the equity of BB Biotech compared to the previous year?
The equity of BB Biotech has increased/decreased by -13.51% decreased compared to the previous year.
What impact does a high equity have on investors of BB Biotech?
A high equity is advantageous for investors of BB Biotech as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of BB Biotech?
A low equity can be a risk for investors of BB Biotech, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of BB Biotech affect the company?
An increase in equity of BB Biotech can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of BB Biotech affect the company?
A reduction in equity of BB Biotech can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of BB Biotech?
Some factors that can affect the equity of BB Biotech include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of BB Biotech so important for investors?
The equity of BB Biotech is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can BB Biotech take to change the equity?
To change equity, BB Biotech can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does BB Biotech pay?
Over the past 12 months, BB Biotech paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BB Biotech is expected to pay a dividend of 0 CHF.
What is the dividend yield of BB Biotech?
The current dividend yield of BB Biotech is .
When does BB Biotech pay dividends?
BB Biotech pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of BB Biotech?
BB Biotech paid dividends every year for the past 0 years.
What is the dividend of BB Biotech?
For the upcoming 12 months, dividends amounting to 0 CHF are expected. This corresponds to a dividend yield of 0 %.
In which sector is BB Biotech located?
BB Biotech is assigned to the '-' sector.
Wann musste ich die Aktien von BB Biotech kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of BB Biotech from 6/11/2024 amounting to 0 CHF, you needed to have the stock in your portfolio before the ex-date on 6/11/2024.
When did BB Biotech pay the last dividend?
The last dividend was paid out on 6/11/2024.
What was the dividend of BB Biotech in the year 2023?
In the year 2023, BB Biotech distributed 0 CHF as dividends.
In which currency does BB Biotech pay out the dividend?
The dividends of BB Biotech are distributed in CHF.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The BB Biotech stock can be added to a savings plan with the following providers: ING
Andere Kennzahlen von BB Biotech
Our stock analysis for BB Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of BB Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.